Cagrilintide
Also known as: AM833
Cagrilintide is an investigational long-acting amylin analogue being studied for weight management, often in combination with semaglutide as CagriSema. It is not an approved medicine.
- Category
- Metabolic / GLP-1
- Reported half-life
- Reported to support once-weekly dosing in trials; not fully established
- Common forms
- Investigational injectable (clinical-trial setting), Studied combined with semaglutide (CagriSema)
- Research status
- Investigational amylin analogue studied alone and as CagriSema with semaglutide. Not approved by the TGA or other regulators at the time of writing.
- Last updated
- 21 June 2026
Claimed effects
The following effects are reported or claimed by users and in early research. They are not established medical facts and many are not supported by large human trials.
- Reported in trials to support weight reduction, particularly when studied with semaglutide
- Reported to reduce appetite and promote a sense of fullness
- Reported to slow gastric emptying in study settings
How it is reported to work
Cagrilintide is described as a long-acting analogue of amylin, a hormone co-secreted with insulin that influences satiety and gastric emptying. By mimicking amylin signalling it is proposed to reduce food intake. These actions are reported from clinical research and are not those of an approved therapy.
Background
Cagrilintide is an investigational amylin analogue studied for weight management. It is frequently discussed alongside semaglutide as part of the combination known as CagriSema. Cagrilintide is not an approved medicine. This page is educational and is not medical advice; it does not recommend use.
What the research shows
Clinical trials have reported effects on body weight, especially when cagrilintide is studied together with semaglutide. These are reported research findings, not established outcomes of an approved product, and results may evolve as further trials report.
| Feature | Reported in research |
|---|---|
| Hormone class | Amylin analogue |
| Studied combination | With semaglutide (CagriSema) |
| Dosing studied | Once-weekly |
What people use it for (reported)
In research discussion, cagrilintide is reported to be of interest for appetite and weight outcomes, particularly because it targets a different pathway (amylin) than the widely discussed GLP-1 medicines. As an investigational compound there is no approved indication anywhere. Material described online as “cagrilintide” is not a verified, approved product, so its identity, purity and contents cannot be assumed, which is why independent testing is discussed in this space.
Things to be aware of
Because cagrilintide is unapproved and experimental, its long-term safety is not established, and the effects reported in trials may not reflect what is sold informally. Reported effects on this page are not confirmed facts; they summarise what research and discussion describe. Anyone with weight or metabolic concerns should consult a qualified healthcare professional for individualised guidance. This article is educational, does not recommend any dose, and does not direct anyone to obtain or use it.
Reported positives & side effects
Compiled from research and community reports. These are reported outcomes, not guarantees or medical advice, individual experiences vary widely.
Reported positives
- Reported in trials to support weight reduction, particularly with semaglutide
- Reported to reduce appetite and promote a sense of fullness
- Reported to slow gastric emptying in study settings
- Reported to complement incretin drugs via a separate amylin pathway
Common side effects
- Reported nausea, especially during dose escalation
- Reported vomiting or diarrhoea
- Reported constipation and reduced appetite
- Reported injection-site reactions
Rare / serious side effects
- Theoretical pancreatitis risk shared across appetite-suppressing injectables
- Reported gallbladder-related events with rapid weight loss
- Reported dehydration from severe gastrointestinal effects
- Reported allergic-type reactions to impurities in unverified product
Reported misuse & overdose risks
What has been reported to happen with overuse, excessive dosing, or long-term misuse of Cagrilintide. Listed so you can make an informed decision, not to suggest any use is safe.
- Because it is investigational, self-dosing outside trials is reported to risk dehydration and electrolyte loss when persistent nausea and vomiting go unmanaged.
- Skipping gradual escalation is reported to provoke severe GI effects and reports of inadequate nutrient intake.
- Combining it with potent incretin drugs without supervision is reported to compound appetite suppression to the point of excessive, rapid weight loss and muscle loss.
- Reliance on unverified research-grade vials is reported to carry dosing-error and contamination risks given no approved standalone formulation.
Reported results timeline
Roughly how long people report it takes to notice effects. A general guide from reports, not a promise, and not advice. Appetite and fullness effects are reported within days, with weight changes reported to develop over months in trial settings.
First effects
Reported early appetite suppression within days
Noticeable change
Reported early weight and fullness changes
Clear results
Reported meaningful weight reduction in trials
Peak effect
Reported continued reduction over longer trial periods
Commonly reported dosing & protocol
Reported figures only, NOT a recommendation or dosing advice. These are numbers people report using, compiled for education so you can make an informed decision. We do not advise anyone to take Cagrilintide. Many peptides are not approved for human use in Australia. Speak to a qualified healthcare professional.
| Route | Subcutaneous injection |
|---|---|
| Typical reported dose | Investigational and NOT approved. Trial-reported doses range roughly 0.3–2.4 mg per week, reached by gradual titration |
| Frequency | Reported as once weekly in trials |
| Cycle length | Trials run over many months with stepwise dose escalation; no established consumer cycle |
Reported reconstitution (mg → units)
Illustration only: a 5 mg vial + 1 mL bacteriostatic water = 5 mg/mL. A 1 mg dose is about 0.2 mL = 20 units on a U-100 insulin syringe.
Work out the units for your vial → CalculatorReported in trials as a once-weekly injection with gradual escalation over months, sometimes paired with semaglutide as CagriSema; framed as trial-derived reporting, not advice. Not approved by the TGA or other regulators.
Best used with / commonly stacked with
Combinations people report using together. Reported, not recommended, stacking can increase risks.
Reported together as CagriSema to combine amylin and GLP-1 pathways
Reported as a comparator incretin agonist in weight discussion
Reported in discussion of layering amylin with multi-receptor agonists
Safety notes
Cagrilintide is an experimental compound without regulatory approval, so its complete safety profile is not established. Reported effects come from controlled trials. Anyone considering weight-management treatment should consult a qualified healthcare professional; cagrilintide is not an approved product in Australia.